InsiderTrades.com logo
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Chan Henry Lee net worth and biography
  • Phone
  • Email
  • Website

Chan Lee Biography and Net Worth

SVP of BeiGene

Mr. Lee previously worked at Sanofi from 2016 to 2022, where he served as North America General Counsel and Head of Legal for the Specialty Care Global Business Unit, responsible for the legal oversight of the company’s U.S. and Canada businesses and its global Specialty Care business. Prior to Sanofi, he held roles of increasing responsibility from 2008 to 2016 at Pfizer, most notably as Chief Counsel for Pfizer’s Innovative Health global business, and, earlier, as Chief Counsel for the Vaccines, Oncology and Consumer Health global businesses, and as Assistant General Counsel for Asia.

Mr. Lee earned his J.D. from the University of California at Berkeley and his B.S. in applied economics from Cornell University.

How do I contact Chan Henry Lee?

The corporate mailing address for Mr. Lee and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Chan Henry Lee's contact information.

Has Chan Henry Lee been buying or selling shares of BeiGene?

Chan Henry Lee has not been actively trading shares of BeiGene within the last three months. Most recently, Chan Henry Lee sold 1,202 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $237.10, for a transaction totalling $284,994.20. Learn More on Chan Henry Lee's trading history.

Who are BeiGene's active insiders?

BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.

Are insiders buying or selling shares of BeiGene?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 95,368 shares worth more than $16,313,435.19. The most recent insider tranaction occured on October, 8th when CEO John Oyler sold 6,175 shares worth more than $1,433,958.50. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.

Information on this page was last updated on 10/8/2024.

Chan Henry Lee Insider Trading History at BeiGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/30/2024Sell1,202$237.10$284,994.20View SEC Filing Icon  
7/30/2024Sell834$160.57$133,915.38View SEC Filing Icon  
7/31/2023Sell791$216.26$171,061.66View SEC Filing Icon  
See Full Table

Chan Henry Lee Buying and Selling Activity at BeiGene

This chart shows Chan Henry Lee's buying and selling at BeiGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BeiGene Company Overview

BeiGene logo
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Read More

Today's Range

Now: $207.93
Low: $207.11
High: $213.88

50 Day Range

MA: $211.09
Low: $188.26
High: $246.04

2 Week Range

Now: $207.93
Low: $126.97
High: $248.16

Volume

278,885 shs

Average Volume

260,336 shs

Market Capitalization

$20.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.